Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$128.91 USD
+0.68 (0.53%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $128.84 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NBIX 128.91 +0.68(0.53%)
Will NBIX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for NBIX
Neurocrine (NBIX) Receives Upgraded Price Target After Strong Earnings
Guggenheim Raises Price Target for NBIX, Maintains "Buy" Rating | NBIX Stock News
Neurocrine price target raised by $10 at Guggenheim, here's why
NBIX: RBC Capital Maintains Rating but Lowers Price Target | NBIX Stock News
NBIX: Stifel Raises Price Target to $174, Reiterates Buy Rating | NBIX Stock News